Product Information
EVEROLIMUS 0.5 MG TABLET is a generic product labeled by Biocon Pharma Inc., priced at $3.5246 per EA under NDC 70377007011. Its NADAC has been published 55 times since Sep 17, 2025.
FDA first approved this application on Apr 9, 2025. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.5 mg/1
Manufacturer
Biocon Pharma Inc.NDC
70377007011
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
EVEROLIMUSApproval Type
Generic (ANDA)
FDA Application
ANDA216140FDA Approved
4/9/2025
TE Code
AB
On Market Since
6/2/2025
Pharmacological Classes
Price Statistics
The NADAC for EVEROLIMUS 0.5 MG TABLET has been published 55 times since Sep 17, 2025, and over the history we have for it it has declined 23.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3.5246 per EA |
|---|---|
| All-time high | $4.6246 (Oct 15, 2025) |
| All-time low | $3.5246 (Sep 23, 2026) |
| 52-week high | $4.6246 |
| 52-week low | $3.5246 |
| Median price | $3.9257 |
| Average price | $3.9576 |
| Largest weekly change | -8.7% (Dec 17, 2025) |
| Weeks tracked | 55 |
| Tracking since | Sep 17, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the EVEROLIMUS market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Biocon Pharma Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
EVEROLIMUS market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Kinase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of EVEROLIMUS 0.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for EVEROLIMUS 0.5 MG TABLET, manufactured by Biocon Pharma Inc., is $3.5246 per EA (NDC 70377007011), effective Sep 30, 2026.
How has the price of EVEROLIMUS 0.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for EVEROLIMUS 0.5 MG TABLET has declined 23.8%. It has been tracked across 55 weekly CMS publications since Sep 17, 2025.
What are the highest and lowest recorded NADAC prices for EVEROLIMUS 0.5 MG TABLET?
Since Sep 17, 2025, the NADAC for EVEROLIMUS 0.5 MG TABLET has ranged from a low of $3.5246 (Sep 23, 2026) to a high of $4.6246 (Oct 15, 2025), with a median of $3.9257 per EA.
Are there cheaper alternatives to EVEROLIMUS 0.5 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of EVEROLIMUS 0.5 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures EVEROLIMUS 0.5 MG TABLET?
EVEROLIMUS 0.5 MG TABLET (NDC 70377007011) is labeled by Biocon Pharma Inc., and CMS classifies it as a generic product.